Blair Willette, PhD, is an investor at KdT Ventures, where she focuses on early-stage investments at the intersection of biology, chemistry, and deep tech. KdT partners with founders building transformative companies across therapeutics, materials, energy, and industrials, with a focus on science-first platforms capable of scaling into meaningful commercial outcomes.Blair brings a rigorous scientific lens to investing, with a PhD in Pharmacology from Duke University, where she focused on G protein-coupled receptor (GPCR) signaling and built tools to interrogate the spatial and temporal dynamics of cellular signaling. She applies this training to deeply evaluate the molecular foundations of new technologies and assess their potential to translate into differentiated processes or products.At KdT, Blair works closely with founders from company formation through early clinical development or commercialization, performing technical diligence and supporting strategy, positioning, and fundraising. Her investment interests span next-generation therapeutics as well as non-healthcare applications of biology and chemistry, including bio-based materials, industrial platforms, and climate technologies.She is particularly passionate about helping scientific founders translate complex innovations into scalable businesses and compelling narratives for investors.